NCT00472186

Brief Summary

This study was designed to determine whether post-operative pain following a tonsillectomy can be reduced by adding an antacid-like medication to the medications taken after surgery. It is hypothesized that even a small amount of stomach acid backing up and entering the mouth can increase post-tonsillectomy pain. Therefore, the use of an antacid-like medication should help to decrease pain and reduce the amount of narcotic medication required for pain control.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started Jun 2008

Typical duration for phase_4

Geographic Reach
1 country

2 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 10, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

May 11, 2007

Completed
1.1 years until next milestone

Study Start

First participant enrolled

June 1, 2008

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2011

Completed
10.9 years until next milestone

Results Posted

Study results publicly available

December 6, 2021

Completed
Last Updated

December 6, 2021

Status Verified

November 1, 2021

Enrollment Period

2.7 years

First QC Date

May 10, 2007

Results QC Date

November 3, 2021

Last Update Submit

November 3, 2021

Conditions

Keywords

TonsillectomyPain

Outcome Measures

Primary Outcomes (1)

  • The Primary Outcome is the Number of Days to Become Free of Narcotic Pain Medication.

    2 weeks

Secondary Outcomes (1)

  • The Secondary Outcomes Are the Number of Days to be Free of Pain, the Number of Days to Return to Normal Activity Levels and the Number of Days to Return to Normal Fluid Intake.

    2 weeks

Study Arms (2)

1

EXPERIMENTAL

Post-operative administration of Lansoprazole

Drug: Lansoprazole

2

PLACEBO COMPARATOR

Placebo

Drug: Placebo

Interventions

If weight is less than 30 kg, 15 mg of Lansoprazole twice daily will be administered. If weight is greater than or equal to 30 kg, 30 mg of Lansoprazole twice daily will be administered.

Also known as: Prevacid
1

Placebo will also be administered based on weight.

2

Eligibility Criteria

Age5 Years - 18 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • All healthy children ages 5-18 years scheduled for tonsillectomy and /or adenotonsillectomy for sleep disturbance secondary to airway obstruction at Children's Hospital Boston

You may not qualify if:

  • Patients on any medications other than the study drug (Lansoprazole or placebo), Amoxicillin®, and acetaminophen with or without codeine
  • An underlying medical condition which would necessitate an alteration in the anesthetic regimen
  • Patients allergic to any of the medications in the protocol
  • History of chronic tonsillitis
  • History of chronic pain conditions
  • History of active gastro-esophageal reflux disease
  • Surgery in addition to tonsillectomy/adenotonsillectomy (except for myringotomy)
  • Cognitive/developmental disorders
  • Inability to use a self-report pain scale

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Children's Hospital Boston

Boston, Massachusetts, 02115, United States

Location

Childrens Hospital Boston

Boston, Massachusetts, 02115, United States

Location

MeSH Terms

Conditions

Pain

Interventions

Lansoprazole

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

2-PyridinylmethylsulfinylbenzimidazolesSulfoxidesSulfur CompoundsOrganic ChemicalsPyridinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsBenzimidazolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Results Point of Contact

Title
Manali Amin, MD
Organization
Dupage Chidlren's ENT & Allergy

Study Officials

  • Manali Amin, MD

    Children's Hosptial Boston

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Instructor

Study Record Dates

First Submitted

May 10, 2007

First Posted

May 11, 2007

Study Start

June 1, 2008

Primary Completion

February 1, 2011

Study Completion

February 1, 2011

Last Updated

December 6, 2021

Results First Posted

December 6, 2021

Record last verified: 2021-11

Locations